There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Adenosine is an endogenous modulator that triggers multiple signaling pathways through four G-protein-coupled adenosine receptors A1R, A2aR, A2bR, and A3R. A2aR and A2bR are the receptors that primarily expressly in immune cells (T cells and myeloid cells, respectively). AB928 is a dual A2aR/A2bR antagonist that inhibits A2aR and A2bR with an equilibrium binding constant of 1.4 and 2 nM, respectively[1]. In the presence of adenosine, human monocyte-derived dendritic cells differentiated and exhibited a reduced ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a mixed lymphocyte reaction. However, the addition of AB928 reversed adenosine-mediated suppression of dendritic cell function. AB928 also rescued gene expressions regulated by adenosine during the differentiation of human monocyte-derived dendritic cells[2]. In human whole blood, AB928 at 90 nM inhibited 50% of the 5 μM 5'-N-Ethylcarboxamidoadenosine-induced phosphorylation of cAMP response element-binding protein[3]. In C57BL/6 mice inoculated with mouse mammary tumor AT3-OVA, the concurrent treatment with AB928 and chemotherapy resulted in a significant reduction in tumor volume as compared to chemotherapy alone (28 mg vs. 86 mg). Also, mice treated with both AB928 and chemotherapy exhibited increased immune cell infiltrate and stromal response in tumors. Treatment with AB928 in combination with α-PD-1 therapy also suppressed the growth of melanoma B16-F10 tumors in inoculated mice[2].
Etrumadenant 细胞实验
Cell Line
Concentration
Treated Time
Description
References
CHO-A2aR cells
10 µM
30 minutes
To evaluate the selectivity of DZD2269 for A2aR and its ability to inhibit cAMP accumulation. Results showed DZD2269 effectively inhibited cAMP accumulation stimulated by 10 µM NECA.
J Exp Clin Cancer Res. 2022 Oct 14;41(1):302
SUIT-2-MSLN
10 nM to 1 μM
24 hours
Assess the effect of AB928 on human anti-MSLN CAR T cells, demonstrating AB928 restored IFN-γ and IL-2 secretion inhibited by NECA.
Br J Cancer. 2022 Dec;127(12):2175-2185
4T1, LL/2-EpCAM, T110299-EpCAM, CT26-EpCAM
100 nM
24 hours
Validate the protective effect of AB928 on CAR T cell function across different cancer cell lines, showing AB928 reversed NECA-mediated suppression in all cell lines.
Br J Cancer. 2022 Dec;127(12):2175-2185
Panc02-EpCAM
100 nM to 10 μM
24 hours
Evaluate the impact of AB928 on CAR T cell cytokine secretion, finding that AB928 fully restored IFN-γ, IL-2, and TNF-α secretion inhibited by NECA.
Br J Cancer. 2022 Dec;127(12):2175-2185
Etrumadenant 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
Colon carcinoma model
Oral
10 mg
Once daily until the end of the experiment
Evaluate the effect of oral AB928 on CAR T cell activation, showing AB928 enhanced CAR T cell activation and promoted an effector-like phenotype.
搜索
HazMat Fee +
